Diluting With Cerebrospinal Fluid Versus Traditional Intrathecal Administration: Antishivering Effects
NCT ID: NCT02189655
Last Updated: 2019-11-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2016-03-31
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Local Infiltration of Liposomal Bupivacaine on Postoperative Analgesia in Patients With Craniotomy Microvascular Decompression
NCT07245290
Patient Controlled Intrathecal Analgesia With Bupivacaine for Chronic Low Back Pain
NCT02886286
Effect of Age on the Median Effective Concentration(EC50) for Motor Block With Spinal Plain Bupivacaine
NCT02141841
The Analgesic Effect of Scalp Nerve Block Using Bupivacaine Liposomes for Postoperative Pain Relief After Craniotomy
NCT07049094
Incidence of TNS After Intrathecal Lidocaine v.s Bupivacaine
NCT03862287
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group Control
Hyperbaric bupivacaine 0.5% 2.5 mL was administered intrathecally in 30 seconds.
No interventions assigned to this group
Group Diluting with cerebrospinal fluid
Hyperbaric bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid was administered intrathecally in 30 seconds
bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid
Hyperbaric bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid was administered intrathecally in 30 seconds
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid
Hyperbaric bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid was administered intrathecally in 30 seconds
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
China Medical University, China
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wen-fei Tan
Department of Anesthesiology, The First Hospital of CMU
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hong Ma, M.D.,Ph.D
Role: STUDY_DIRECTOR
The First Hospital of CMU
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
the First Hospital of China Medical University
Shenyang, Liaoning, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20140630
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.